Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process

Leonardo Freire-de-Lima, Kirill Gelfenbeyn, Yao Ding, Ulla Mandel, Henrik Clausen, Kazuko Handa and Sen-itiroh Hakomori
Proceedings of the National Academy of Sciences of the United States of America
Vol. 108, No. 43 (October 25, 2011), pp. 17690-17695
Stable URL: http://www.jstor.org/stable/41352579
Page Count: 6
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process
Preview not available

Abstract

The process termed "epithelial-mesenchymal transition" (EMT) was originally discovered in ontogenic development and has been shown to be one of the key steps in tumor cell progression and metastasis. Recently, we showed that the expression of some glycosphingolipids (GSLs) is down-regulated during EMT in human and mouse cell lines. Here, we demonstrate the involvement of GalNAc-type (or mucintype) O-glycosylation in EMT process, induced with transforming growth factor β (TGF-β) in human prostate epithelial cell lines. We found that: (i) TGF-β treatment caused up-regulation of oncofetal fibronectin (onfFN), which is defined by mAb FDC6, and expressed in cancer or fetal cells/tissues, but not in normal adult cells/tissues. The reactivity of mAb FDC6 requires the addition of an O-glycan at a specific threonine, inside the type III homology connective segment (IIICS) domain of FN. (ii) This change is associated with typical EMT characteristics; i.e., change from epithelial to fibroblastic morphology, enhanced cell motility, decreased expression of a typical epithelial cell marker, E-cadherin, and enhanced expression of mesenchymal markers. (iii) TGF-β treatment up-regulated mRNA level of FN containing the IIICS domain and GalNAc-T activity for the IIICS domain peptide substrate containing the FDC6 onfFN epitope. (iv) Knockdown of GalNAc-T6 and T3 inhibited TGF-β-induced up-regulation of onfFN and EMT process, (v) Involvement of GSLs was not detectable with the EMT process in these cell lines. These findings indicate the important functional role of expression of onfFN, defined by sitespecific O-glycosylation at IIICS domain, in the EMT process.

Page Thumbnails

  • Thumbnail: Page 
[17690]
    [17690]
  • Thumbnail: Page 
17691
    17691
  • Thumbnail: Page 
17692
    17692
  • Thumbnail: Page 
17693
    17693
  • Thumbnail: Page 
17694
    17694
  • Thumbnail: Page 
17695
    17695